With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Viking Therapeutics reported updated, early-stage study results on its oral obesity drug candidate. Vertex Pharmaceuticals said the first patient with sickle cell disease was treated with Casgevy, its ...

The company’s shares opened today at $3.15. Samimy covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Viking Therapeutics, and Apellis Pharmaceuticals. According to ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector. YouTuber MrBeast becomes the 8th ...

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

Constellation Energy stock is lower Monday as a regulatory decision offsets the utility company's solid third-quarter ...